cas 125278-10-6|| where to buy (2S)-1,1,1-trifluoropropan-2-amine

Nom du produit:(2S)-1,1,1-trifluoropropan-2-amine

IUPAC Name:(2S)-1,1,1-trifluoropropan-2-amine

Unité d'emballage	Stock disponible	Prix($)	Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 125278-10-6 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:125278-10-6; Formule moléculaire:C3H6F3N; Point de fusion:-; Code SMILES:C[C@H](N)C(F)(F)F; Densité:

: Numéro de catalogue:CM362048; Poids moléculaire:113.08; Point d'ébullition:; N° Mdl:; Stockage:

: Fluorinated Compounds; Fluorine is the most electronegative element in the periodic table, and the fluorine atom has a small atomic radius, so fluorine-containing organic compounds have many wonderful properties. For example, the introduction of fluorine atoms or fluorine-containing groups into drug molecules can improve the permeability to cell membranes, metabolic stability and bioavailability; in addition, the introduction of fluorine atoms will improve the lipid solubility of the compound and promote its absorption in the body. The speed of delivery changes the physiological effect. In the field of medicinal chemistry, the introduction of fluorine atoms into organic molecules is an important direction for the development of new anticancer drugs, antitumor drugs, antiviral agents, anti-inflammatory drugs, and central nervous system drugs.

: Povorcitinib; Incyte announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib, an oral JAK1 inhibitor, in adult patients with prurigo nodularis (PN). These data were presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting.
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for PN.